Cefixime (trihydrate)

Cefixime trihydrate (FR-17027 trihydrate) is an antibiotic and a third generation cephalosporin antibiotic, useful for the treatment of a number of bacterial infections[1][2].

Product Specifications

CAS Number

[125110-14-7]

Product Name Alternative

FR-17027 (trihydrate) ; FK-027 (trihydrate) ; CL-284635 (trihydrate)

UNSPSC

12352005

Hazard Statement

H317, H334

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/cefixime-trihydrate.html

Purity

99.77

Solubility

10 mM in DMSO

Smiles

O=C(C(N12)=C(C=C)CS[C@@H]2[C@H](NC(/C(C3=CSC(N)=N3)=N\OCC(O)=O)=O)C1=O)O.[H]O[H].[H]O[H].[H]O[H]

Molecular Formula

C16H21N5O10S2

Molecular Weight

507.50

Precautions

H317, H334

References & Citations

[1]Neu HC, et al. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime. Pediatr Infect Dis J. 1987 Oct;6 (10) :958-62.|[2]Unemo M, et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012 Mar;56 (3) :1273-80.|[3]Matsumoto Y, et al. Antibacterial activity of cefixime against Salmonella typhi and applicability of Etest. J Infect Chemother. 1999 Sep;5 (3) :176-179. |[4]Connolly KL, et al. Pharmacokinetic Data Are Predictive of In Vivo Efficacy for Cefixime and Ceftriaxone against Susceptible and Resistant Neisseria gonorrhoeae Strains in the Gonorrhea Mouse Model. Antimicrob Agents Chemother. 2019 Feb 26;63 (3) :e01644-18.|[5]Shi Y, et al. Restoration of cefixime-induced gut microbiota changes by Lactobacillus cocktails and fructooligosaccharides in a mouse model. Microbiol Res. 2017 Jul;200:14-24.|[6]Stone JW, et al. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother. 1989 Feb;23 (2) :221-8.